"10.1371_journal.pone.0135388","plos one","2015-09-14T00:00:00Z","Vadim I Krivokrysenko; Ilia A Toshkov; Anatoli S Gleiberman; Peter Krasnov; Inna Shyshynova; Ivan Bespalov; Ratan K Maitra; Natalya V Narizhneva; Vijay K Singh; Mark H Whitnall; Andrei A Purmal; Alexander N Shakhov; Andrei V Gudkov; Elena Feinstein","Cleveland BioLabs, Inc. (CBLI), Buffalo, New York, United States of America; Armed Forces Radiobiology Research Institute (AFRRI), Bethesda, Maryland, United States of America; Department of Cell Stress Biology, Roswell Park Cancer Institute (RPCI), Buffalo, New York, United States of America","Conceived and designed the experiments: VIK AVG EF. Performed the experiments: ASG PK IB RKM NVN VKS AAP ANS. Analyzed the data: VIK IAT ASG VKS IS AAP ANS AVG EF. Contributed reagents/materials/analysis tools: MHW. Wrote the paper: VIK AVG EF.","The authors of this manuscript have the following competing interests: VIK, IAT, ASG, AAP, ANS, AVG and EF are shareholders of Cleveland Biolabs, the company that develops entolimod and holds the intellectual property rights for this drug. There are four patentsâ€”all with the same title and inventors, all assigned to Cleveland Biolabs: title: Flagellin related polypeptides and uses thereof and numbers: 8,932,609; 8,871,215; 8,287,882; 8,007,812. PK, IS, IB, RKM and NVN are employees of Cleveland BioLabs, Inc. AVG and EF are consultants of Cleveland Biolabs. AVG is a Member of Board of Directors of Cleveland Biolabs. There are no additional patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2015","09","Vadim I Krivokrysenko","VIK",14,TRUE,3,8,9,3,TRUE,TRUE,FALSE,0,NA,FALSE
